Fig. 2: PFS and OS by age subgroup. | Leukemia

Fig. 2: PFS and OS by age subgroup.

From: Daratumumab/lenalidomide/dexamethasone in transplant-ineligible newly diagnosed myeloma: MAIA long-term outcomes

Fig. 2

Kaplan–Meier estimates of (A) PFS in patients aged <70 years, ≥70 to <75 years, and ≥75 years; (B) PFS in patients aged ≥80 years; (C) OS in patients aged <70 years, ≥70 to <75 years, and ≥75 years; and (D) OS in patients aged ≥80 years. PFS progression-free survival, OS overall survival, D-Rd daratumumab plus lenalidomide/dexamethasone, Rd lenalidomide/dexamethasone, HR hazard ratio, CI confidence interval, NR not reached.

Back to article page